NDAINHALATIONGAS
Approved
Aug 2013
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
MEDICAL AIR, USP (medical air) by United Therapeutics. Approved for idiopathic pulmonary fibrosis. First approved in 2013.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEDICAL AIR, USP is an inhaled gas product approved by the FDA for Idiopathic Pulmonary Fibrosis (IPF), a progressive lung disease characterized by scarring of lung tissue. As a medical gas administered via inhalation, it represents a non-pharmacological therapeutic approach to managing this serious respiratory condition. The product operates at the intersection of respiratory medicine and medical device/gas therapy.
Peak
Product is at peak commercial maturity with established market presence; teams are likely focused on maintaining market share against small-molecule competitors rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on MEDICAL AIR, USP at United Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.